Cerus Stock News

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST. A live webcast of the event will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event. ABOUT CERUS Cerus Co

The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive

Cerus Corp''s (NASDAQ: CERS ) Q4 FY21 product revenue was $39.9 million , compared to $28.2 million, driven by increased sales of INTERCEPT platelet kits to blood center customers across the U.S. Total revenue increased 49% to $50.1 million, beating the consensus of $44.2 million. Product gross profit was $20.4 million and, for the second consecutive quarter, was the highest in the company''s history, Full story available on Benzinga.com

CERS earnings call for the period ending December 31, 2021.

CERS earnings call for the period ending December 31, 2021.

Cerus press release (CERS): Q4 GAAP EPS of -$0.05 beats by $0.03.Revenue of $39.87M (+41.4% Y/Y) in-line.The Company is reiterating its 2022 annual product revenue guidance range of

Strong Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $50.1 Million Grew 49% in the Fourth Quarter Product Revenue of $39.9 Million Grew 41% in the Fourth | February 22, 2022

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021. Recent developments and highlights include: Fourth quarter 2021 total revenue of $50.1 million, reflecting a 49% increase over the prior year period. For the full year, 2021 total revenue was $159.5 million, reflecting a 40% increase over the prior year period. Total revenue was composed of (in thousands, except %): Three Months E

Cerus Corporation (CERS) CEO Obi Greenman on Q4 2021 Results - Earnings Call Transcript

Cerus (NASDAQ:CERS) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is -$0.08 (+11.1% Y/Y) and the consensus

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides,

DUBLIN , Feb. 7, 2022 /PRNewswire/ -- The "Global Blood Purification Equipment Market 2021-2031 by Product (Hemodialysis, Blood Filtration, CRRT, Hemoperfusion, Plasma Exchange Device), Portability (Portable, Stationary), Indication, End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com''s offering. The global blood purification equipment market will reach $21.08 billion by 2031, growing by 5.5% annually over 2021-2031, driven by the increasing prevalence of blood-related diseases, rising geriatric population, technological innovations, growing healthcare expenditure, rising adoption of home based healthcare, and the rising health consciousness amid COVID-19 pandemic. This report is based on a comprehensive research of the entire global blood purification equipment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

Cerus provided 2022 product revenues guidance of a record $157 to $164 million, after delivery of better than expected 2021 product revenues of $130.9 Million (42% higher than 2020 product revenues).